Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18997720 | 1.00 | KDM4E (0.61) | KDM4ETP53SMN1; SMN2NPC1LMNA | |
| SCHEMBL18997696 | 0.88 | KDM4E (0.61) | KDM4ETP53SMN1; SMN2NPC1LMNA | |
| SCHEMBL25314481 | 0.88 | LMNA (0.64) | KDM4ETP53SMN1; SMN2NPC1LMNA | |
| SCHEMBL25316122 | 0.88 | LMNA (0.64) | KDM4ETP53SMN1; SMN2NPC1LMNA | |
| SCHEMBL18997699 | 0.88 | KDM4E (0.59) | KDM4ETP53SMN1; SMN2NPC1LMNA | |
| SCHEMBL21901297 | 0.88 | KDM4E (0.58) | KDM4ETP53SMN1; SMN2NPC1LMNA | |
| SCHEMBL23222371 | 0.87 | KDM4E (0.58) | KDM4ETP53SMN1; SMN2NPC1LMNA | |
| SCHEMBL25315245 | 0.86 | SMN1; SMN2 (0.61) | KDM4ETP53SMN1; SMN2NPC1LMNA | |
| SCHEMBL25318037 | 0.85 | LMNA (0.60) | KDM4ETP53SMN1; SMN2NPC1LMNA | |
| SCHEMBL30484184 | 0.85 | LMNA (0.64) | KDM4ETP53SMN1; SMN2NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | claimed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | KDM4E 4699/4885TP53 1638/4885SMN1; SMN2 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.